Biomarker-guided treatment of congestive heart failure.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Congestive Heart Failure

• Publication date

  2010-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1751-7133.2010.00169.xPMID 20653714
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The STARBRITE trial: a randomized, pilot study of B-type natriuretic peptide-guided therapy in patients with advanced heart failure.

  2011cited by this paper
• N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial.

  2009cited by this paper
• BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial.

  2009cited by this paper
• Long-Term Trends in First Hospitalization for Heart Failure and Subsequent Survival Between 1986 and 2003: A Population Study of 5.1 Million People

  2009cited by this paper
• Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study.

  2007cited by this paper
• The effects of medications on circulating levels of cardiac natriuretic peptides

  2007cited by this paper
• Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony.

  2006cited by this paper
• American Heart Association--scientific sessions 2005. 13-16 November 2005, Dallas, TX, USA.

  2006cited by this paper
• Changes in Brain Natriuretic Peptide and Norepinephrine Over Time and Mortality and Morbidity in the Valsartan Heart Failure Trial (Val-HeFT)

  2003cited by this paper
• Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations.

  2000cited by this paper
• Plasma levels of brain and atrial natriuretic peptides elevate in proportion to left ventricular end-systolic wall stress in patients with aortic stenosis.

  1997cited by this paper
• Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy.

  1996cited by this paper
• Hospital admissions and deaths due to congestive heart failure in New Zealand, 1988-91.

  1995cited by this paper
• Localization and Mechanism of Secretion of B‐Type Natriuretic Peptide in Comparison With Those of A‐Type Natriuretic Peptide in Normal Subjects and Patients With Heart Failure

  1994cited by this paper
• Plasma brain natriuretic peptide in assessment of acute dyspnoea.

  1994cited by this paper
• Different Secretion Patterns of Atrial Natriuretic Peptide and Brain Natriuretic Peptide in Patients With Congestive Heart Failure

  1993cited by this paper
• Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: effect of stretching.

  1993cited by this paper
• Plasma brain natriuretic peptide and atrial natriuretic peptide concentrations correlate with left ventricular end‐diastolic pressure

  1993cited by this paper
• The effect of intravenous saline loading on plasma levels of brain natriuretic peptide in man

  1993cited by this paper
• Brain natriuretic factor: regional plasma concentrations and correlations with haemodynamic state in cardiac disease.

  1993cited by this paper
• Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.

  1991cited by this paper
• Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

  1988cited by this paper
• Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

  1987cited by this paper
• Long‐term Vasodilator Therapy for Heart Failure: Clinical Response and its Relationship to Hemodynamic Measurements

  1981cited by this paper

• Evaluation of Serum NT-Pro Brain Natriuretic Peptide Levels in Neonates with Respiratory Distress

  2018cites this paper
• Diagnostic Accuracy of NT-ProBNP for Heart Failure with Sepsis in Patients Younger than 18 Years

  2016cites this paper
• Inflammatory Markers Associated With Disease Progression of Cardiorenal Syndrome

  2015cites this paper
• Determining the optimal cutoff values of plasma N-terminal pro-B-type natriuretic peptide levels for the diagnosis of heart failure in children of age up to 14 years.

  2014cites this paper
• Red cell distribution width predicts short- and long-term outcomes of acute congestive heart failure more effectively than hemoglobin

  2014cites this paper
• Heart Failure Biomarkers

  2013cites this paper
• Role of the NT-proBNP level in the diagnosis of pediatric heart failure and investigation of novel combined diagnostic criteria

  2013cites this paper
• Brain natriuretic peptide-guided therapy in the inpatient management of decompensated heart failure

  2012cites this paper
• Time-dependent Cox regression: serial measurement of the cardiovascular biomarker proadrenomedullin improves survival prediction in patients with lower respiratory tract infection.

  2012cites this paper